Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
November 2, 2023
Earnings Call Speaker Segments
Chris Taylor
executiveThanks, operator. Hello, everyone, and good morning. It's a pleasure to have you join us for the Agios Third Quarter 2023 Conference Call. Slides for today's call are available in the Investors section at agios.com. With me today are Brian Goff, our Chief Executive Officer; Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, Chief Financial Officer. Before we begin, please note that certain statements made during this call will be forward-looking. As a result of various risks, uncertainties and other factors, including those described in our most recent filings with the SEC and any future filings we may make with the SEC, actual events and results could differ materially from those expressed or implied by any forward-looking statements. I'll now hand the call over to Brian.
Brian Goff
executiveAppreciate that, Chris. Morning to all of you, and thanks for being here with us. What we're aiming to do at Agios is create a top-tier hematology business, with approvals reaching across a range of indications, plus a broader portfolio driven by careful business development and by moving forward an in-house pipeline that matches what we know best — rare disease. It's a pleasure to talk with you today about how far we've come so far this year and to point to several key clinical and regulatory milestones coming up over the next few months. We've been gathering steam, and we've notched up plenty of wins: in the clinic, on the commercial side, and through strategic business development. Above all, we've pushed our pipeline forward substantially thanks to strong execution in clinical development, to consistent and persuasive clinical data, and to investigators' excitement about what PK activation could do in our lead indications; beyond the milestones we've already hit, I'm happy to share that we've dosed our first patient in the Phase 3 portion of the RISE UP study of mitapivat in sickle cell disease, and we finished enrolling the Phase 3 ACTIVATE-kidsT study of mitapivat in pediatric PK deficiency sooner than planned. Given that progress, we expect to deliver 6 mid- to late-stage data readouts by the end of 2025, with 3 of those arriving by the end of next year, and we're still in a strong position to create considerable value both near term and long term. Sarah will walk you through our R&D progress in detail in just a few minutes. As Tsveta will tell you, we take encouragement from the fact that the durable efficacy seen in the clinical trials of mitapivat in PK deficiency keeps showing up as a low discontinuation rate among real-world patients. What matters is that we keep getting the most out of the current PK deficiency launch while also building up our commercial capabilities to back the launches we expect down the road in substantially larger patient populations, among them a possible thalassemia launch in 2025. Cecilia will tell you that we closed the third quarter with roughly $872 million in cash and investments on the balance sheet. We're delighted to have brought in a promising early-stage siRNA asset from Alnylam during the last quarter, and we keep looking for ways to grow and diversify our pipeline in a disciplined way. We're also watching Servier's march toward FDA approval of vorasidenib closely, since we hold retained economics. As for what lies ahead, we expect to hit every one of our remaining 2023 milestones and to move our priorities forward next year. In particular, we're aiming to report top line data from the Phase 2a study of AG-946 in lower-risk MDS before the year is out. And before this year ends as well, we intend to file the IND for our PA stabilizer for treating phenylketonuria, or PKU. As we head into the next year, additional items on our list are getting ready for 2 Phase 3 data readouts for energized and energized tea in thalassemia in the coming year, increasing enrollment in the Phase III segment of the RISE UP trial of mitapivat in sickle cell disease, and wrapping up enrollment in the Phase 3 ACTIVATE-kids trial of mitapivat in pediatric PK deficiency. On the whole, I'm quite happy about the substantial strides we achieved in 2023, and I'm eager to close out the year on a high note; having said that, I'll hand the call over to Sarah now.
Sarah Gheuens
executiveThank you, Brian. Over the course of this year, we've achieved enormous strides in moving forward our industry-leading pipeline of PK activators, and I want to express gratitude to our research and development team for the commitment and unwavering dedication they show toward bettering patients' lives. Mirroring that momentum, we're genuinely enthusiastic about the ASH Annual Meeting coming up in December and eager to engage with a wide range of stakeholders regarding what we've accomplished in PK deficiency, thalassemia, sickle cell disease, patient advocacy, and beyond. We plan to reveal further specifics about our ASH presentations once they become available later this morning. Several of you may have noticed that, in the ASH online program, the Congress organizers have—for the first time ever—dedicated an educational session to PK activation as a treatment for hereditary hemolytic anemia, called Energizing the Red Cell: Novel Therapy for Hereditary Hemolytic Anemia. During this session, prominent KOLs will deliver talks addressing the therapeutic potential of PK activation in PK deficiency, sickle cell disease, and thalassemia. As the frontrunners in PK activation, we were obviously thrilled by this recognition. As Brian mentioned, we have recently given the first dose to a patient in the Phase III portion of the RISE UP trial of mitapivat for sickle cell disease, and our team is working hard to bring sites on board. Brian and I were able to join the Sickle Cell Disease Association of America National Convention in the D.C. area only a couple of weeks back, and it really drove home why this work matters. Listening to what these patients deal with every day strengthened our connection with the sickle cell disease community and renewed Agios' commitment through both patient advocacy and clinical progress. Now let's move to AG-946, our second PK activator. Enrollment in the Phase 3 trial in lower-risk MDS has moved faster, so we expect to share top line data from that study before the year is over. Just to give some context, MDS refers to a group of rare blood cancers that don't behave the same way in every patient. A hallmark of the condition is ineffective hematopoiesis, which tends to bring on anemia. It's worth noting that about 70% of MDS cases fall into the lower-risk category, and those cases share key disease mechanisms with other blood disorders we're working on. The Phase 2a trial we're running lasts 16 weeks and enrolls 20 patients. Its primary endpoints are hemoglobin response — meaning an average gain of no less than 1.5 grams per deciliter compared with baseline, measured between week 8 and week 16 — and transfusion independence, which means going without a transfusion for a minimum of 8 weeks in a row. The main goal here is to show proof of concept for AG-946 in patients who have low-risk MDS, and then by looking at what the results tell us, figure out whether any changes to the protocol would make sense as we think about moving ahead into Phase 2b. Brian touched on this briefly — we remain on schedule to hit every one of the milestones we still have left in 2023. Before the year is out, we anticipate submitting the IND for our PAH stabilizer, which stands for phenylalanine hydroxylase, targeting the underlying cause of PKU, or phenylketonuria. For the pediatric work we've been doing, we've finished bringing patients into the Phase 3 ACTIVATE-kidsT trial, which is testing mitapivat in kids who have PK deficiency and receive regular transfusions — and that happened a number of months sooner than we had planned. In the parallel Phase 3 ACTIVATE-kids study, which looks at mitapivat in children with PK deficiency who don't get regular transfusions, the team hit its target of getting at least half of the study's patients enrolled before the year ended, and attention has now shifted to getting enrollment finished. And then there's the TMPRSS6 siRNA we brought in through a recent in-license from Alnylam; it's now part of our portfolio, and everyone is eager to start moving that program forward as a possible disease-modifying therapy for polycythemia vera. As we think about the coming year, top line results are anticipated from the Phase 3 ENERGIZE and ENERGIZE-T trials of mitapivat in thalassemia. Taken together, those trials look at mitapivat across every thalassemia subtype, covering alpha as well as beta thalassemia, and patients spanning the entire range of transfusion burden. In ENERGIZE, the main measure we're looking at is how hemoglobin responds — that's defined as a rise of at least 1 gram per deciliter in the average hemoglobin level between week 12 and week 24 compared with where patients started. For ENERGIZE-T, the key endpoint is whether transfusions go down, which we define as at least a 50% reduction in units of spread blood cells that were transfused, plus a drop of 2 units or more in transfused red blood cells at any point across 12 consecutive weeks up to week 48, again measured against baseline. These trial designs let us demonstrate clinical meaningfulness in several different ways — whether that's a gain in hemoglobin, which is supported by less fatigue and/or needing fewer transfusions. Since enrollment moved along at such a fast clip, we expect results from ENERGIZE during the opening six months of next year, while findings from ENERGIZE-T should come through in the latter six months of next year. On that note, I'll pass things over to Tsveta.
Tsveta Milanova
executiveThank you, Sarah. Our commercial team stays dedicated to seizing the fullest potential from the ongoing launch in PK deficiency, since that will serve as the groundwork for possible upcoming introductions in thalassemia, sickle cell disease, and lower-risk MDS. During Q3 of 2023, we brought in $7.4 million in net PYRUKYND revenue, which is 10% higher than the previous quarter. Altogether, 160 patients have finished a prescription enrollment form, among them 13 during the third quarter of 2023, marking a 9% rise compared with the second quarter. That resulted in a net total of 100 patients receiving therapy as Q3 ended. We keep seeing PEF conversion timelines spanning 4 to 6 weeks. Those receiving therapy continue to come from an expanding and varied prescriber group of 142 physicians and reflect a wide range of demographics and disease manifestations that aligns with the adult PK deficiency population; we still anticipate gradual, consistent adoption over time along with quarter-over-quarter fluctuation. This stems from how ultra-rare the disease is and the lengthy lag between spotting a possible prescriber and then turning that into a PEF and eventually a patient on therapy. We stay committed to efficiently pinpointing providers who are likely to treat adults with PK deficiency and remain encouraged by how persistent patient treatment has been. Everything we do to develop our strengths in targeting analytics, physician awareness and education, and patient access is assisting us in constructing a solid base to capture the fullest potential from possible upcoming introductions in substantially bigger patient groups. The earliest of these expected introductions is in thalassemia, where mitapivat could become the first therapy capable of enhancing hemolytic anemia and ineffective erythropoiesis throughout the entire spectrum of disease subtypes, covering alpha and beta thalassemia, plus transfusion-dependent and nontransfusion-dependent thalassemia. Crucially, unmet need remains elevated across thalassemia subtypes. Roughly 60% of leukemia patients in the U.S. lack an approved treatment option. As shown on this slide, unlike PK deficiency, the thalassemia market in the U.S. is more mature, with a greater diagnosed prevalence and stronger disease awareness. PK deficiency is an ultra-rare disease, encompassing about 3,000 patients with an estimated diagnosis rate of 30%. By comparison, thalassemia affects roughly 8,000 patients in the U.S. The diagnosis rate for thalasemia is elevated, thanks to the presence of targeted new-born screening. Furthermore, thalassemia has firmly established ICD-10 codes. Having claims data available in thalassemia will let us apply the strengths we are developing now to guide our segmentation, targeting, and education work for launch. From examining this data, we have determined that about half of adult thalassemia patients receive treatment at fewer than 150 affiliated hematology and oncology, academic, and community practices. As a result, we intend to direct our initial launch push toward the Lasenia centers of excellence, along with these affiliated academic and community practices. As the rollout moves forward, we expect to bring in more community practices that have patients under routine monitoring; since possible upcoming launches for thalassemia and sickle cell disease are getting closer, the chance to reach a wider group of patients we treat makes us very enthusiastic. So with that, I'll hand the call over to Cecilia now.
Cecilia Jones
executiveAppreciate that, Tsveta. You can find our Q3 2023 financial results in this morning's press release, and our 10-Q, being filed later today, will carry additional detail. Let me take a moment now to give some context and call out several key points. Net PYRUKYND revenue for the third quarter of 2023 came in at $7.4 million, which is $0.7 million higher than Q2 2023. Because of the variability Tsveta just mentioned, third quarter revenue fell short of what we had expected. Given how ultra-rare this disease is and the long lead times tied to getting patients started on therapy, our expectation remains slow and steady growth, with quarter-to-quarter variability, going forward. As with other rare disease launches, gross to net should land in the 10% to 20% range annually. Cost of sales for the quarter totaled $0.6 million. R&D expenses for the third quarter were $81.8 million, up $16.9 million versus the third quarter of 2022; the main driver of that increase was the $17.5 million upfront payment to Alnylam for the TMPRSS6 asset. SG&A expenses for the third quarter were $25.8 million, down $3.3 million versus the third quarter of 2022. That was mainly due to lower stock-based compensation expense and professional fees. As a reminder, through the divestiture of our oncology business to Servier, we keep rights to a potential $200 million milestone upon FDA approval of vorasidenib plus 15% royalties on potential U.S. net sales. We closed the quarter with cash, cash equivalents and marketable securities of roughly $872.4 million. We expect this balance, along with anticipated product revenue, interest income and the potential for an afatinib milestone, to let the company fund operating expenses and capital expenditures through several value-creating milestones at least into 2026. This guidance excludes cash inflows from potential vorasidenib royalties, from commercializing mitapivat outside the U.S. through one or more partnerships, or from other potential strategic business or financial agreements. We stay focused on creating shareholder value, including by proactively managing our cost base and taking a disciplined approach to cash allocation as we get ready to support potential future launches of PYRUKYND. As we head toward a different set of potential value-creating milestones in the near term, I'm confident our strong balance sheet lets us execute from a position of strength as we keep pursuing ways to create shareholder value. I'll now hand the call back to Brian for his closing remarks.
Brian Goff
executiveThanks, Cecilia. Through this year so far, we've achieved a great deal in moving toward the vision we hold for Agios. I'm eager for the catalyst-heavy stretch that lies in front of us, with data readouts from 3 mid- to late-stage trials anticipated before next year ends. As we always do, we'll keep working to act as responsible stewards of our balance sheet and to assess meaningful chances for creating value. Last, I want to express gratitude to each of our employees for the effort and commitment they bring to our mission of changing the lives of patients who live with rare diseases, as well as to all of our partners, among them the patients, physicians, caregivers and participants in our clinical development programs. With that said, we'll now take questions on the call.
Divya Rao
analystThis is Divya, filling in for Mark. Congratulations on the quarter. Regarding the MDS readout, might you provide a bit more detail about what that readout will cover? And I suppose, does the team hold any internal threshold for defining success, and for what you must observe prior to advancing into the Phase 3 portion?
Brian Goff
executiveThank you, Divya. Sarah, would you like to handle that?
Sarah Gheuens
executiveOkay, so like we said, we've arranged how this program's enrollment works so that we can produce a readout during this year, before this year is over. What you should anticipate lines up pretty much with the way we've dealt with top-line data results previously. So there's more coming on that front. Naturally, complete specifics will always be held back for a medical meeting. So that's something being worked on as well. As for your question about whether we have a bar — yes, a bar exists; keep in mind this is a Phase 2a. Obviously, we're counting on the study to give us learnings and, like we've said, we'll make certain the data gets reviewed and that we position things for a Phase 2b to maximize success.
Brian Goff
executiveI'd also like to take a moment to give credit once more to Sarah and her group for pulling this off, since initially we had thought this would come in the following year, yet enrollment moved along much more quickly than we had anticipated. So we're really eager for the data readout.
Salveen Richter
analystFollowing up on that final question, could you walk us through what lies ahead for AG-946, explain where it sits in the larger pipeline, and describe how it relates to PYRUKYND?
Brian Goff
executiveSure, I can handle that one. To start, having more than a single PK activator puts us in an excellent spot. There are several reasons for that, and IRA happens to be one of them, since it affords us considerable optionality. As you're aware, 946 is being advanced right now along two separate paths. Sarah covered one of them — our work in low-risk MDS — and we're quite enthusiastic about the chance to obtain that data readout. The second path is a Phase 1 trial of 946 in sickle cell disease. The primary goal behind it is to generate data in a different hemolytic anemia. Depending on how that readout appears when the timing is right, we'll be steered toward whatever else we'd want to pursue with 946. Still, looking at the big picture and from a franchise standpoint, plenty of optionality exists, along with multiple opportunities ahead of us.
Tessa Romero
analystCould you help us understand what kinds of analyses will be included when the complete RISE UP presentation happens at a medical meeting later in the year — the ones that go past the top line we already saw?
Sarah Gheuens
executiveAbsolutely. Thank you, Tess. As you'd expect from us — since this is what we always do whenever we read out data — you'll be getting additional detail on our secondary endpoints, because up to now that hasn't been shared in the press release. So there will be more specifics on hemolytic parameters, that sort of thing. And naturally, safety too. With our standard method, we remain committed to intent to treat, so what you'll see is precisely the primary and secondary endpoints, exactly as we characterized them in the protocol.
Tessa Romero
analystAll right, and we're eager for that ASH abstract to come out — plus a small item on this front.
Brian Goff
executiveSo are we. Appreciate it, Tess.
Gregory Renza
analystThis is < > calling in for Greg. Congratulations on the advancement. I've got a question regarding AG-946. To begin, could you remind us — you said before that there's heterogeneity within low-risk MDS. Could you remind us how patients who are transfused or have a low transfusion burden differ from those with a high transfusion burden that we enrolled in Phase 2b, and why 946's mechanism might be able to address a broader set of populations? And secondly, there were questions earlier about the bar for success, but can you pose the question differently. I was wondering whether we ought to view those early data processes at 30% to 40%, obviously transfusion independence, as a bar for competitiveness?
Sarah Gheuens
executiveAppreciate the question. Let me take the final portion first. Comparing studies to designs that aren't really head-to-head simply isn't valid. The patients who get enrolled aren't the same. How long each study runs isn't the same either. Because of that, pulling a bar out of one study and dropping it onto another one just doesn't work in my view. On the population side: the initial part is a brief study where we deliberately targeted people receiving fewer transfusions, which lets us genuinely look at what occurs in that group. Then 2b runs longer, and there we're at ease enrolling a group carrying a greater transfusion burden. Among all these different groups, it really comes down to nothing more than a numeric threshold, and that's all there is to it.
Greg Harrison
analystWhat's your view on the added commercial possibility in pediatric PKD? To what extent are these patients well characterized, and what identification work is still left on your side? Also, if there's a loss here, should we expect a similar pattern to the one you've observed among adults?
Tsveta Milanova
executiveThanks for asking. For sure. When considering the PKD patient population overall, our expectation is roughly 3,000 to 8,000 patients across the U.S; and EU5. That means approximately 3,000 patients within the U.S. An estimated 80% of them are outpatient population. That works out to roughly 20% of the pediatric. And because this disease is so outrate in nature, our expectation would be loan dynamics that are very similar. That said, we'll remain in the market far longer, with greater experience with PYRUKYND and a deeper understanding of the disease. So our hope is to reach these patients as fast as we can.
Brian Goff
executiveGreg, beyond the commercial potential Tsveta just mentioned, I want to add something. We feel it matters a great deal that these PKD trials get run and finished, since that provides a strong safety signal as we look toward the considerably bigger chances we discuss constantly — thalassemia and sickle cell disease. That's the second aspect here: I believe the community, the investigators, and the patients who'll be following this were quite eager to see those data readouts.
Greg Harrison
analystThat's useful. Could you share any further detail right now about discontinuations during this launch phase? And if giving a number isn't possible yet, should we anticipate a point later on when that becomes available?
Tsveta Milanova
executiveAs we've mentioned previously, we keep moving forward with the launch and gain new knowledge daily. Because PKD is an ultra-rare disease, our expectation is gradual, consistent advancement as time goes on, alongside quarter-over-quarter fluctuation. What I can share is that, quite significantly, patient persistency remains strong. Provider feedback has been favorable, and payers back the product. As a result, the rate of discontinuation is still low. The patient population we're working with is small, which explains why you may notice certain shifts in these metrics.
Sarah Gheuens
executiveBeyond that, the rate of people stopping treatment in the clinical trial for also is small, which lets us genuinely examine how the effect holds up across the various open-label extensions we currently have running, and that continues to look promising.
Alex Nackenoff
analystThis is Alex filling in for Danielle. One more thing regarding 946 before the MBS data comes out. I'm just wondering what your current perspective is on the magnitude of the thrombocytopenia risk tied to that toxicity signal. I realize the dose being used isn't the one where it shows up, but I was somewhat curious whether there's something specific to MDS that might leave these patients more vulnerable to that signal.
Sarah Gheuens
executiveAbsolutely. I appreciate the question. Let me begin with the latter portion of what you asked... Thrombocytopenia is in fact seen more often among patients who have MDS, since they may be inclined toward developing pancytopenia, and that involves a reduction in platelets. This is inherent to their condition; and in fact, a number of the treatments list thrombocytopenia as another adverse event. As you noted, we did see thrombocytopenia at the higher dose — the 20-milligram dose — among healthy volunteers. However, at this time we're evaluating 5 milligrams in the MDS patient population, and we're striving to genuinely grasp both the safety profile and the efficacy profile of the drug. So there will be more information on that once we have a database log.
Brian Goff
executiveSarah also frequently points out that this can be tracked, can be controlled, and can be turned around — which is quite heartening too.
Sarah Gheuens
executiveAbsolutely. That is also feedback we get directly from doctors, since this is a process happening inside the organ system they already know well while managing all those blood-related conditions. The fact that low platelet counts can be detected through lab work and then addressed by possibly stopping the treatment is quite reassuring.
Brian Goff
executiveOkay, so I really appreciate everyone taking part in today's call. You saw the news earlier today — our team holds a strong belief that we can bring transformative new therapies to patients and create substantial long-term value for shareholders, and the ongoing work our team keeps putting in makes me genuinely proud. So thank you for your interest in Agios, and we're very much looking forward to talking with you before long. Many thanks.
Operator
operatorThis concludes today's conference call. Thank you all for participating. You may disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.